So far two drugs, pirfenidone [acting via TGF-β (transforming growth factor beta) inhibition] and nintedanib (a pan-tyrosine kinase receptor inhibitor) have been approved for IPF patients. The gene discussed is NTRK1; the disease is idiopathic pulmonary fibrosis.